A Message From Stansberry Research

Dear Reader,

I believe Elon Musk is about to launch a new device that could kill the iPhone.

It's rumored to be thinner... have longer battery life... and sell for much cheaper...

It could also be usable worldwide without cell towers... and run on one of the most powerful AI-based platforms in existence.

I call it "Starphone" (see why here)...

And I'm convinced this new device could quickly unlock some of the biggest Elon gains you've ever seen.

This marks the third major mobile phone prediction of my career...

In 2004, I told Congress the smartphone was about to transform the world – years before the iPhone was first announced.

Had you bought $1,500 worth of Apple shares back then, they'd now be worth million.

A few years later, as a hedge fund trader, I told Steve Cohen at SAC Capital that Apple wouldn't sell 1.2 million phones like every other analyst was predicting... but 1 billion phones.

Both predictions came true.

Now, I'm sharing all the evidence proving why I believe Elon is working on a new device...

One that could not only change your life and our society... but potentially make you 50 times your money as it hits shelves.

Just know that this story is already starting to hit the mainstream.

Just last week, the FCC gave Elon a major green light to move ahead with his mobile plans.

That means your window to move your money is NOW — before the official debut.

Get the full story and see all the government filings and deals here.

Regards,

Josh Baylin
Frmr. Bloomberg Reporter
Frmr. SAC Capital
Senior Tech Expert, Stansberry Research

P.S. I'm also sharing the name and ticker of a stock at the very heart of this huge story. It's 100% free, on this page here.

3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead

Submitted by Jessica Mitacek. Date Posted: 10/10/2026.

Small-cap stocks tend to fly under the radar. Often in the startup stage, these companies may lack analyst coverage, be overlooked by institutional investors and remain illiquid because of low average trading volume.

But occasionally, some small capspresent investment theses that are so compelling they begin to command attention.

Three biotech companies—Inventiva (NASDAQ: IVA), Larimar Therapeutics (NASDAQ: LRMR) and Ascentage Pharma Group International (NASDAQ: AAPG)—have catalysts that could put them on more investors' radars.

Each is developing treatments for serious diseases with significant unmet medical needs, and all three carry consensus analyst price targets suggesting triple-digit upside. While clinical, regulatory and financial risks remain substantial, upcoming drug-development milestones could help determine whether Wall Street's optimism is justified.

Inventiva's Phase 3 MASH Results Could Be a Major Stock Catalyst

Headquartered in France, Inventiva is a clinical-stage pharmaceutical company developing an investigational oral therapy for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease associated with metabolic disorders.

Inventiva’s most promising product, lanifibranor, is an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist that simultaneously activates all three PPAR subtypes.

The drug is currently being evaluated in the company's Phase 3 NATiV3 trial, with topline results expected in Q4 2026. Positive results could support a potential U.S. regulatory submission in the first half of 2027, making the upcoming readout a significant catalyst for investors.

While MASH affects approximately 5% of adults globally, an estimated 9 million to 15 million U.S. adults suffer from the disease. Its prevalence is forecast to rise substantially because of increasing rates of obesity, insulin resistance, type 2 diabetes and metabolic syndrome.

As a clinical-stage biopharma with no approved commercial products, Inventiva is pre-revenue. While lanifibranor works its way through the pipeline, the company has seen its net losses mount, increasing annually from $34 million in 2019 to $416 million in 2025.

Shares are down more than 58% from their one-year high, but the stock carries an analyst consensus Buy rating, and its $15.86 price target indicates more than 400% upside potential.

Larimar Moves Closer to FDA Approval for Its Lead Drug

Larimar Therapeutics is a clinical-stage biotech company focused on developing treatments for rare diseases caused by deficiencies in mitochondrial proteins.

Its lead drug candidate, nomlabofusp, is an engineered fusion protein designed to deliver frataxin to mitochondria. It is being developed primarily to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder.

Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, aiming to address an underlying cause of the disease rather than merely treating its symptoms.

Because its therapies remain in the development stage, Larimar is also pre-revenue. As a result, the company’s net losses have been increasing, from $35 million in 2022 to $166 million in 2025.

On June 29, Larimar announced that it submitted the first module of its rolling Biologics License Application to the U.S. Food and Drug Administration for accelerated approval of nomlabofusp. The remaining modules are expected to be submitted before the end of 2026.

Shares are down 58% from their one-year high, and short interest of 13.93% of the float remains a concern. However, analysts have given LRMR a consensus Buy rating and assigned it a $10.33 price target, which implies more than 280% potential upside.

Ascentage's China Success Sets the Stage for U.S. Expansion

Of the three stocks on this list, shares of Ascentage Pharma Group International have fared the worst over the past year, having fallen nearly 64% from their one-year high.

The commercial-stage pharmaceutical company focuses on developing therapies that target mechanisms involved in programmed cell death, or apoptosis, primarily for cancer and other serious diseases. Its pipeline includes small-molecule drug candidates designed to inhibit proteins that help cancer cells survive.

Two of its leading candidates are lisaftoclax and APG-115. Lisaftoclax is a BCL-2 inhibitor already approved in China for certain previously treated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, with additional clinical trials underway in other hematologic malignancies. APG-115 is an MDM2-p53 inhibitor under evaluation for oncology applications.

Ascentage has also developed candidates targeting inhibitor-of-apoptosis proteins, along with other treatments relevant to cancer care.

The company conducts research and clinical-development activities in China and has pursued international development and regulatory opportunities, including in the United States. While some of its drugs are already approved in China, others remain subject to clinical testing and regulatory review, and approved uses may vary by geography.

It is important to note that, unlike the other two companies, Ascentage generates commercial revenue.

In its Aug. 19 H1 2026 earnings release, which covers the first six months of 2026, the company reported revenue of $44.5 million, up 29% year over year. The increase was primarily driven by sales of its oncology drugs, including olverembatinib and lisaftoclax.

The stock carries a consensus Buy rating from analysts, who have given AAPG a $44.75 price target, suggesting more than 200% potential upside.